Metrics as of 10/15/2026, 08:26 AM (Berlin time), refresh in progress.
Bicycle Therapeutics Stock
Bicycle Therapeutics plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Kevin Lee
- Employees
- 288
- Market cap
- $240 M
- IPO
- 23/05/2019
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate…
Bicycle Therapeutics stock: price history
1D
-3.9%
1W
-11.1%
1M
-4.9%
6M
-35.1%
YTD
-51.1%
1Y
-60.0%
2Y
-87.4%
5Y
-94.2%
10Y
–
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~11% weaker price swings than usual
Ask the agents about Bicycle Therapeutics
Analyst assessment of Bicycle Therapeutics
PRICE TARGET LOW
US$12.00
CONSENSUS
US$12.00
MEDIAN
US$12.00
PRICE TARGET HIGH
US$12.00
0
STRONG BUY
17
BUY
4
HOLD
0
SELL
0
STRONG SELL
21
TOTAL · Buy
As of: 30/07/2026
Bicycle Therapeutics stock metrics
P/E
-1.27
P/B
0.47
EV/EBITDA
1.4
RETURN ON EQUITY
-9.9%
NET MARGIN
-8,002.1%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.6%
FLOAT SHARES
62,005,352
AVG. DAILY VOLUME (30D)
505,638
Insider transactions (SEC)
Perry Jennifer Scott
Skynner Michael
Skynner Michael
Lee Kevin
Lee Kevin
Institutional holders
Comparable stocks
Frequently asked questions about Bicycle Therapeutics stock
What does Bicycle Therapeutics do?
Bicycle Therapeutics plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Kevin Lee, the company employs around 288 people.
The IPO was on 23/05/2019; the stock trades on NASDAQ under the ticker BCYC.
What do analysts say about Bicycle Therapeutics stock?
21 analysts rate the stock, the consensus is Buy (as of 30/07/2026).
The average price target is US$12.00, ranging from US$12.00 to US$12.00, with a median of US$12.00.
This is an external assessment, not a statement by Market Jury.
When does Bicycle Therapeutics report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly -11% stronger than usual.
Does Bicycle Therapeutics pay a dividend?
No, Bicycle Therapeutics currently does not pay a dividend.
Which stocks are comparable to Bicycle Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Bicycle Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Bicycle Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.